Human Plasma Like Medium Market Report 2026

The human plasma derived products market size has grown strongly in recent years. It will grow from $0.91 billion in 2025 to $0.99 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increasing use of immunoglobulin therapies, growing prevalence of rare and chronic disorders, rising demand for albumin and clotting factors, expansion of plasma collection centers, and increasing awareness of plasma-derived treatments.

The human plasma derived products market size is expected to see strong growth in the next few years. It will grow to $1.38 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to growing demand for immunoglobulin therapies, rising incidence of immunodeficiency diseases, increasing healthcare expenditure on biologics, expansion of plasma fractionation capacity, and growing adoption of plasma-derived products in emerging markets. Major trends in the forecast period include technology advancements in plasma fractionation, innovation in virus inactivation methods, developments in recombinant and hybrid plasma products, research and development in next generation plasma therapies, and integration of digital systems in plasma collection and processing.

The increasing demand for in-vitro diagnostics (IVD) tests is expected to propel the growth of the human plasma-like medium market going forward. In-vitro diagnostics are laboratory tests performed on biological samples such as blood, tissues, or bodily fluids to detect diseases, monitor health conditions, and guide treatment decisions. The rising use of IVD tests is driven by an aging global population and the growing prevalence of chronic and infectious diseases, which necessitate early detection and continuous monitoring. Human plasma-like medium supports in-vitro diagnostics and related research by providing physiologically relevant cell culture conditions required for accurate disease modeling, assay validation, and therapeutic development. For instance, in March 2025, according to NHS England, a UK-based government health authority, the number of diagnostic tests conducted in Community Diagnostic Centres increased from 1,498,000 in 2023/24 to 2,328,300 in 2024/25, representing a 55.6% year-over-year increase. Therefore, the rising demand for in-vitro diagnostics is driving the growth of the human plasma-like medium market.

The growing demand for gene therapies is also expected to fuel the human plasma-like medium market growth. Gene therapy is a medical approach that involves modifying, replacing, or regulating defective genes to treat or prevent disease. Demand for gene therapies is increasing due to advancements in genetic sequencing and precision diagnostics, which enable accurate identification of disease-causing genetic mutations and support targeted therapeutic development. Human plasma-like medium plays a critical role in gene therapy research by providing a physiologically relevant environment that enhances cell viability, growth, and functional performance during gene delivery, expression analysis, and treatment evaluation. This enables more reliable assessment of therapeutic efficacy under conditions that closely mimic the human body. For example, in December 2024, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit scientific organization, the US Food and Drug Administration (FDA) approved six gene therapy products in 2023, up from five approvals in 2022. Therefore, the growing adoption of gene therapies is driving the growth of the human plasma-like medium market.

Major participants in the human plasma-like medium market are prioritizing the development of advanced culture supplements, including scalable animal-free options, to enhance consistency, safety, and ethical standards across cell culture and biomanufacturing processes. A scalable animal-free alternative is defined as a biologically derived growth medium ingredient that substitutes conventional animal-based supplements, delivering reliable performance while avoiding variability, ethical issues, and contamination risks linked to animal materials. For example, in April 2025, PL Bioscience Inc., a biotechnology firm based in the US, introduced an artificial human platelet lysate intended for cell culture use as a scalable animal-free replacement for traditional platelet lysate and serum supplements. This engineered medium component enables strong cell growth and viability while removing dependence on animal-derived inputs, making it appropriate for translational research, regenerative medicine, and large-scale cell therapy production.

Major companies operating in the human plasma like medium market are Thermo Fisher Scientific Inc., Sigma Aldrich Chemicals Private Limited, Sartorius AG, HiMedia Laboratories Private Limited, Biological Industries Israel Beit Haemek Ltd., PAN-Biotech GmbH, AMS Biotechnology (Europe) Ltd., Plasmax LLC, Avam Biotechnologies Ltd.

North America was the largest region in the human plasma like medium market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human plasma like medium market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the human plasma like medium market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are impacting the human plasma like medium market by increasing costs of imported raw biochemical components, amino acids, growth factors, stabilizers, and precision manufacturing equipment. research institutions and biopharmaceutical companies in north america and europe are most affected due to reliance on specialized imported inputs, while asia-pacific faces higher costs for export-oriented production. these tariffs are raising procurement expenses and extending research timelines. however, they are also encouraging local sourcing of reagents, regional production capabilities, and innovation in cost-optimized medium formulations.

Human plasma-like medium is a specialized cell culture medium formulated to closely replicate the biochemical composition of human blood plasma. It contains physiologically relevant concentrations of amino acids, salts, glucose, vitamins, metabolites, and growth-supporting components to create an in vivo-like environment for cell growth and experimentation. This medium is widely used to enhance physiological relevance, reproducibility, and predictive accuracy in in vitro cell culture studies across biomedical research, drug discovery, toxicology, and disease modeling applications.

The primary product types of human plasma-like medium include liquid and powder formats. Liquid plasma-like medium provides ready-to-use culture conditions that closely mimic human plasma for cell growth and research applications. Distribution channels include direct sales, distributors, and online platforms. Applications include cell culture, drug discovery, regenerative medicine, and others, among academic institutes, biopharma companies, CROs, hospitals, laboratories, and others.

The human plasma like medium market consists of sales of standardized human plasma-like culture media, serum-free plasma-like media, custom-formulated plasma-like media, and specialized supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.